SEA medtech supply chains need redesign to support growth: KPMG

The region offers strong demand, but regulatory fragmentation and internal complexity could constrain expansion.

Southeast Asia’s medtech supply chains need to be deliberately redesigned to support the region’s growth potential, according to KPMG.

In its report, KPMG said the region, with a population of more than 700 million, has become a critical growth market for global medtech companies.

Supportive government healthcare policies are helping expand healthcare infrastructure and increase procedural volumes, improving access to healthcare across the region.

Global medtech companies are targeting sustained double-digit growth in Southeast Asia and are expected to invest more deeply in manufacturing and distribution once key markets reach sufficient scale.

However, KPMG warned that the supply chain could become a major constraint in the near to medium term if it is not redesigned to fit the region’s structural complexities.

The report identified two key challenges: internal complexity and external fragmentation.

Internally, SKU counts have expanded across many Southeast Asian markets, partly due to continued demand for legacy products linked to government funding and tender decisions. This has increased planning requirements, safety-stock needs, and working capital investment.

To address these challenges, KPMG said companies should focus on three priorities: improving end-to-end supply chain visibility, strengthening distributor collaboration, and adopting selective localization.

End-to-end visibility should be the foundation, supported by demand sensing, control towers, integrated business planning, and direct access to consumption-level data through hospital apps, digital ordering platforms, and connected devices.

KPMG said medtech companies should also shift from loose distributor arrangements to more structured, performance-based partnerships, with clear KPIs, governance, continuous improvement processes, and compliance expectations.

As Southeast Asia remains largely distributor-led, stronger distributor collaboration can reduce execution variability, improve compliance, and support expansion into Tier-2 and Tier-3 cities.

The report also recommended selective localization instead of full replication of manufacturing footprints in each country. Companies should localize only what is needed to meet tender, local-content, or regulatory expectations.

Without a clear scope, KPMG warned that localization could create duplicated processes, fragmented compliance pathways, and higher overheads.

KPMG also called for collective industry action, saying individual company transformation cannot fully offset the costs and delays caused by regulatory fragmentation and non-harmonized customs processes.

Whilst Southeast Asia has foundational frameworks such as the ASEAN Medical Device Directive and the Regional Comprehensive Economic Partnership, KPMG said these could remain policy concepts unless regional coordination improves.

The firm said real impact will require regulatory reliance, harmonized documentation, and fewer duplicative audits.

KPMG said Southeast Asia has the ingredients to become a resilient and efficient medtech supply chain hub, supported by strong demand, evolving policy frameworks, and improving operational capabilities.

However, it said successful companies will be those that engineer supply chains suited to a region defined by fragmented regulation and shared demand.